Reprogramming immune cells to fight brain cancer
Targeting macrophage reprogramming in glioblastoma
This study is looking at how to change certain immune cells in the brain that usually help glioblastoma grow, so they can instead help fight the cancer, focusing on a specific receptor called GPR183, with the hope of finding better treatments for patients with this tough-to-treat brain cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cleveland Clinic Lerner Com-Cwru NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11126127 on NIH RePORTER |
What this research studies
This research focuses on glioblastoma, a highly aggressive brain cancer with a poor prognosis. It aims to understand how certain immune cells, specifically tumor-associated macrophages, can be reprogrammed from promoting tumor growth to fighting against it. The study will investigate the role of a specific receptor, GPR183, in these immune cells and how it influences their behavior in the tumor environment. By targeting this mechanism, the research seeks to develop new therapeutic strategies that could enhance the effectiveness of existing treatments for glioblastoma.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with glioblastoma who are seeking new treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to innovative therapies that improve survival rates and quality of life for patients with glioblastoma.
How similar studies have performed: Previous research has shown promise in targeting immune cell reprogramming in various cancers, suggesting potential success for this novel approach in glioblastoma.
Where this research is happening
Cleveland, United States
- Cleveland Clinic Lerner Com-Cwru — Cleveland, United States (Active)
Researchers
- Principal investigator: Chen, Peiwen — Cleveland Clinic Lerner Com-Cwru
- Study coordinator: Chen, Peiwen
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.